ArticleCurrent oncology (Toronto, Ont.)2021
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
Open access · goldAbstract readConsensus Statement
In one paragraph
Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- The Genetic Landscape of Colorectal Cancer: From Molecular Alterations to Therapeutic Decision Pathways.Cancers · 2026Review
- Clinicopathologic and molecular spectrum of gastrointestinal stromal tumor (GIST) with NTRK fusion and marked response to larotrectinib in GIST with NTRK fusion: a case report.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Article
- Current landscape and future trends in salivary gland oncology research-a bibliometric evaluation.Gland surgery · 2024Article
- Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation.Diagnostic pathology · 2024Article
- Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1.International journal of clinical oncology · 2024Article
- Consensus Recommendations to Optimize the Detection and Reporting ofCurrent oncology (Toronto, Ont.) · 2023Review
- Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.Respirology case reports · 2022Article
- Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- A pharmacological exploration of targeted drug therapy in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2022Review
- Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.BMC cancer · 2022Article
- TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.Current oncology (Toronto, Ont.) · 2022Article
- Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.European journal of endocrinology · 2022Article
- Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers.European thyroid journal · 2022Article
- Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline.Therapeutic advances in medical oncology · 2022Review
- Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.Current oncology (Toronto, Ont.) · 2021Article
- Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.Current oncology (Toronto, Ont.) · 2021Article
- Safety of current treatment options for NTRK fusion-positive cancers.Expert opinion on drug safetyReview
- Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors.Clinical pathology (Thousand Oaks, Ventura County, Calif.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 1 country.
D Gwyn BebbTom Baker Cancer Centre and University of Calgary, Calgary, AB T2N 4N2, Canada.
Shantanu BanerjiResearch Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.
Normand BlaisCentre Hospitalier Universitaire de Montreal, Department of Medicine, University of Montreal, Montreal, QC H2X 3E4, Canada.ORCID 0000-0003-2698-4362
Patrice DesmeulesService D'Anatomopathologie et de Cytologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, QC G1V 0A6, Canada.
Sharlene GillBC Cancer, Vancouver, BC V5Z 4E6, Canada.
Andrea GrinDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Harriet FeilotterDepartment of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.ORCID 0000-0002-1388-2183
Aaron R HansenDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Martin HyrczaDepartment of Pathology and Laboratory Medicine, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 4Z6, Canada.ORCID 0000-0002-9633-3293
Monika KrzyzanowskaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Barbara MeloskyBC Cancer, Vancouver, BC V5Z 4E6, Canada.
Jonathan NoujaimHôpital Maisonneuve-Rosemont, Montreal, QC H1T 2M4, Canada.
Bibiana PurginaThe Ottawa Hospital, Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Dean RuetherDepartment of Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.
Christine E SimmonsBC Cancer, Vancouver, BC V5Z 4E6, Canada.
Denis SoulieresCentre Hospitalier Universitaire de Montreal, Department of Medicine, University of Montreal, Montreal, QC H2X 3E4, Canada.
Emina Emilia TorlakovicDepartment of Pathology and Laboratory Medicine, Saskatchewan Health Authority and University of Saskatchewan, Saskatoon, SK S7N 5B5, Canada.
Ming-Sound TsaoDepartment of Pathology, Laboratory Medicine Program, University Health Network, Toronto, ON M5G 2C4, Canada.ORCID 0000-0002-9160-5405
University Health Network · CACentre Hospitalier de l’Université de Montréal · CAQueen's University · CAUniversity of Calgary · CACancerCare Manitoba · CAHôpital Maisonneuve-Rosemont · CAInstitut universitaire de cardiologie et de pneumologie de Québec · CAOccupational Cancer Research Centre · CASaskatchewan Health Authority · CAUniversity of Ottawa · CA
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsAdultBiomarkersCanadaConsensusHumansReceptor, trkABiomarkersReceptor, trkAentrectiniblarotrectinibmolecular testingNTRKoncogenic driverstargeted therapyTRK fusiontumour-agnostic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.